Watch ALGS. Know when insiders buy.
One email the day a filing lands. Free.
ALGS
Aligos Therapeutics, Inc.
6.21
−0.01 −0.16%
USD · close Sep 4
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
67
PASS · shorts 67
Insiders, 90 days
0
no open-market filings in 90 days
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $264.6MP/E —DIV YIELD —FCF YIELD —REV TTM $3.7M +19.4%NET INCOME −$76MNET CASH —52W 4.08 – 13.30SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | $0 | −100.0% | — | −$1.9M | −$1.5M | — | -0.14 | −$24.9M | — | — | Aug 6 |
| Q1 2026 · Mar 31 | $2.8M | +810.0% | — | −$26.9M | −$23M | −153.5% | -2.21 | −$23.1M | — | — | Aug 6 |
| Q4 2025 · Dec 31derived | $169K | −72.1% | — | −$21.8M | −$19.9M | — | -2.01 | −$21.7M | — | — | Mar 5 |
| Q3 2025 · Sep 30 | $741K | −40.7% | — | −$28.4M | −$31.5M | — | -3.04 | −$24.3M | — | — | Nov 6 |
| Q2 2025 · Jun 30 | $965K | −9.0% | — | −$18.6M | −$15.9M | −413.4% | -1.53 | −$15.5M | — | — | Aug 6 |
| Q1 2025 · Mar 31 | $311K | −55.2% | — | −$19.2M | $43.1M | — | -2.11 | −$20.9M | — | — | Aug 6 |
| Q4 2024 · Dec 31derived | $606K | −9.8% | — | −$20.6M | −$82.2M | — | -13.10 | −$18.4M | — | — | Mar 5 |
| Q3 2024 · Sep 30 | $1.3M | +15.2% | — | −$20.1M | −$19.3M | — | -3.07 | −$20.1M | — | — | Nov 6 |
| Q2 2024 · Jun 30 | $1.1M | — | — | −$26.4M | $5.1M | — | 0.81 | −$19.5M | — | — | Nov 6 |
| Q1 2024 · Mar 31 | $694K | — | — | −$22M | −$34.9M | — | -5.58 | −$22.7M | — | — | Nov 6 |
| Q4 2023 · Dec 31derived | $672K | — | — | −$26M | −$27.9M | — | 0.39 | −$22.7M | — | — | Mar 10 |
| Q3 2023 · Sep 30 | $1.1M | — | — | −$19.1M | −$18M | — | -10.37 | −$20.3M | — | — | Nov 6 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | $2.2M | — | −$88M | −$24.2M | -1106.7% | -2.45 | −$82.5M | — | — | — | — |
| FY2024 · to Dec 31 | $3.6M | — | −$89.2M | −$131.2M | -3633.6% | -20.94 | −$80.7M | $130K | −$80.9M | — | — |
| FY2023 · to Dec 31 | $6.2M | — | −$88.1M | −$87.7M | -1416.2% | -34.20 | −$79M | $19K | −$79M | — | — |
| FY2022 · to Dec 31 | $0 | — | −$97.6M | −$96M | — | -2.25 | −$79.4M | $943K | −$80.3M | — | — |
| FY2021 · to Dec 31 | $0 | — | −$128.3M | −$128.3M | — | -3.22 | −$115.7M | $892K | −$116.6M | — | — |
| FY2020 · to Dec 31 | $0 | — | −$97.8M | −$108.5M | — | -10.87 | −$74.3M | $2.1M | −$76.3M | — | — |
Every number comes from Aligos Therapeutics, Inc.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.